Howe & Rusling’s Adverum Biotechnologies ADVM Stock Holding History

Howe & Rusling’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-2	Closed	–	–	1023
2015 Q2	$0	Buy	+2	New	+$675	﹤0.01%	1044

Other funds holding ADVM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Howe & Rusling's ADVM Position: Q3 2015 in Review

Howe & Rusling sold out of Adverum Biotechnologies (ADVM) in Q3 2015, closing a stake of 2 shares.

Howe & Rusling first reported a position in ADVM in Q2 2015 and held it in 1 quarter. The position peaked at $0 in Q2 2015. 92 funds tracked by Wall St. Rank hold ADVM as of Q3 2015.

Howe & Rusling reported no remaining Adverum Biotechnologies position as of Q3 2015 after selling out during the quarter.
Howe & Rusling sold 2 Adverum Biotechnologies shares in Q3 2015.
Howe & Rusling first reported a position in Adverum Biotechnologies in Q2 2015 and held it in 1 quarter.
Howe & Rusling's Adverum Biotechnologies position peaked at $0 in Q2 2015.
92 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2015.

Based on Howe & Rusling's 13F filing for Q3 2015, filed 10 Nov 2015.